Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 234

The DOI matches its Crossref record.

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

von Pawel, Joachim, Gatzemeier, Ulrich, Pujol, Jean-Louis, Moreau, Lionel, Bildat, S., Ranson, Malcolm, Richardson, Gary, Steppert, Claus, Rivière, Alain, Camlett, Ina, Lane, Stephen, Ross, Graham · 2001 · Journal of Clinical Oncology

Abstract

PURPOSE: Topotecan, administered intravenously, is active in small-cell lung cancer (SCLC). In this study, the comparability of oral topotecan to IV topotecan was investigated. PATIENTS AND METHODS: Patients with SCLC that had relapsed 90 days or more after cessation of initial chemotherapy were randomized to receive either oral topotecan (Hycamtin) 2.3 mg/m 2/d × 5 (52 patients) or IV topotecan 1.5 mg/m 2/d × 5 (54 patients), every 21 days. RESULTS: Response rates in this phase II randomized study were 23% (12/52) in the oral topotecan arm and 15% (8/54) in the IV topotecan arm. All radiological responses were confirmed by an independent radiologist. Median survival was 32 weeks (oral) and 25 weeks (IV). Good symptom control, defined as sustained improvement or no deterioration, was evident in both treatment groups. Topotecan was generally well tolerated, with myelosuppression being the major toxicity. Grade 4 neutropenia occurred in 35.3% of patients on oral topotecan and in 67.3% of patients on IV topotecan, which was statistically significant (P = .001). Fever/infection more than or equal to grade 2 associated with grade 4 neutropenia, together with sepsis, occurred in only 5.1% of courses (oral) and 3.3% of courses (IV). Non-hematological toxicity consisted mainly of vomiting (oral: 36.5% of patients; IV: 31.5% of patients) and nausea (oral: 26.9% of patients; IV: 40.7% of patients). CONCLUSION: This study found oral topotecan to be similar in efficacy to IV topotecan in the treatment of patients with relapsed SCLC, sensitive to first-line chemotherapy, with less grade 4 neutropenia and greater convenience of administration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.6.1743

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 234

Metadata

Authors
von Pawel, J., Gatzemeier, U., Pujol, J.-L., Moreau, L., Bildat, S., Ranson, M., Richardson, G., Steppert, C., Rivière, A., Camlett, I., Lane, S., & Ross, G.
Venue
Journal of Clinical Oncology
Published
2001-03-15
Volume
19
Issue
6
Pages
1743-1749
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1859729923
Cited by
234
References
0
FWCI
8.28
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1200/jco.2001.19.6.1743
The paper
von Pawel, J., Gatzemeier, U., Pujol, J.-L., Moreau, L., Bildat, S., Ranson, M., Richardson, G., Steppert, C., Rivière, A., Camlett, I., Lane, S., & Ross, G. (2001). Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.6.1743

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.